Long-term health-related quality of life of patients receiving extended-release tolterodine for overactive bladder

American Journal of Managed Care

Volumn 8, Issue 19 SUPPL., 2002, Pages

  Kelleher, Con J ^a   Kreder, Karl J ^a   Pleil, Andreas M ^a   Burgess, Somali Misra ^a   Reese, Pat Ray ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TOLTERODINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVALESCENCE; COPING BEHAVIOR; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; EMOTION; ENERGY; EVIDENCE BASED MEDICINE; FEMALE; HEALTH STATUS; HUMAN; HUMAN RELATION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; OVERACTIVE BLADDER; PHYSICAL DISABILITY; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SIDE EFFECT; SLEEP; SOCIAL ASPECT; STATISTICAL SIGNIFICANCE; SYMPTOM; URINE INCONTINENCE;

EID: 0036930323     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Abrams P, Kelleher CJ, Kerr LA, Rogers RG. Overactive bladder significantly affects quality of life. Am J Manag Care. 2000;6(suppl):S580-S590.
2. Wein AJ, Rovner ES. The overactive bladder: An overview for primary care health providers. Int J Fertil. 1999;44:56-66.
3. Johannesson M, O'Connor RM, Kobelt-Nguyen G, Mattiasson A. Willingness to pay for reduced incontinence symptoms. Br J Urol. 1997;80:557-562.
4. O'Conor RM, Johannesson M, Hass SL, Kobelt-Nguyen G. Urge incontinence: Quality of life and patient's valuation of symptom reduction. Pharmacoeconomics. 1998;14:531-539.
5. Kobelt G. Economic considerations and outcomes measurement in urge incontinence. Urology. 1997;50(suppl 6A):100-107.
6. Grimby A, Svanborg A. Morbidity and health related quality of life among ambulant elderly citizens. Aging Clin Exp Res. 1997;9:356-364.
7. Samuelsson E, Victor A, Tibblin G. A population study of urinary incontinence and nocturia among women aged 20-59 years. Acta Obstet Gynecol Scand. 1997;76:74-80.
8. Wyman JF, Fantl JA, McClish DK, et al. Quality of life following bladder training in older women with urinary incontinence. Int Urogynecol J. 1997;8:223-229.
9. Norton PA, MacDonald LD, Sedgwick PM, Stanton SL. Distress and delay associated with urinary incontinence, frequency and urgency in women. Br Med J. 1988;297:1187-1189.
10. Schlenk EA, Erlen JA, Dunbar-Jacob J, et al. Health-related quality of life in chronic disorders: A comparison across studies using the MOS SF-36. Qual Life Res. 1998;7:57-65.
11. Coyne L, Schmier J, Hunt T, et al. Developing a specific HRQL instrument for overactive bladder [abstract]. Value Health. 2000;3:141.
12. Grimby A, Milsom I, Molander U, Wiklund I, Ekelund P. The influence of urinary incontinence on the quality of life of elderly women. Age Ageing. 1993;22:82-89.
13. Hunskaar S, Visnes A. The quality of life in women with urinary incontinence as measured by the Sickness Impact Profile: Erratum. J Am Geriatr Soc. 1992;40:976-977.
14. Kelleher CJ, Cardozo LD, Toozs-Hobson PM. Quality of life and urinary incontinence. Curr Opin Obstet Gynecol. 1995;7:404-408.
15. Kelleher CJ, Cardozo LD, Khullar V, Salvatore S. A new questionnaire to assess the quality of life of urinary incontinent women. Br J Obstet Gynaecol. 1997;104:1374-1379.
16. Lenderking WR, Nackley JF, Anderson RB, Testa MA. A review of the quality-of-life aspects of urinary urge incontinence. Pharmacoeconomics. 1996;9:11-23.
17. Abrams P, Freeman R, Anderstrom C, Mattiasson A. Tolterodine, a new antimuscarinic agent: As effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol. 1998;81:801-810.
18. Chancellor M, Freedman S, Mitcheson HD, et al. Tolterodine, an effective and well tolerated treatment for urge incontinence and other overactive bladder symptoms. Clin Drug Invest. 2000;19:83-91.
19. Van Kerrebroeck P, Kreder K, Jonas U, Zinner N, Wein A. Tolterodine once-daily: Superior efficacy and tolerability in the treatment of the overactive bladder. Urology. 2001;57:414-421.
20. Pleil AM, Reese PR, Kelleher CJ, Okano GJ. Health-related quality of life of patients with overactive bladder receiving immediate-release tolterodine. HEPAC. 2001;2:69-75.
21. Kreder K, Mayne C, Jonas U. Long-term tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder. Eur Urol. 2002;41:588-595.
22. Chancellor M, Freedman S, Mitcheson HD, et al. Tolterodine, an effective and well tolerated treatment for urge incontinence and other overactive bladder symptoms. Clin Drug Invest. 2000;19:83-91.
23. Kelleher CJ, Cardozo LD, Toozs-Hobson PM. Quality of life and urinary incontinence. Curr Opin Obstet Gynecol. 1995;7:404-408.
24. Kelleher CJ, Cardozo LD, Khullar V, Salvatore S. A new questionnaire to assess the quality of life of urinary incontinent women. Br J Obstet Gynaecol. 1997;104:1374-1379.
25. Kobelt G, Kirchberger I, Malone-Lee J. Review. Quality-of-life aspects of the overactive bladder and the effect of treatment with tolterodine. BJU Int. 1999;83:583-590.
26. Conway K, Uzun V, Marrel A, et al. Linguistic validation of the King's Health Questionnaire (KHQ) in eight languages [abstract]. Value Health. 1999;2:204.
27. Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey: Manual and Interpretation Guide. Boston, Mass: Health Assessment Lab, New England Medical Center Health Institute; 1993.
28. Ware JE, Kosinski M, Keller SD. SF-36 Physical & Mental Health Summary Scales: A User's Manual. Boston, Mass: Health Assessment Lab, New England Medical Center Institute; 1994.
29. McHorney CA, Ware JE, Lu RJF, Sherbourne CD. The MOS 36-item short-form health survey (SF-36) III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care. 1994;32:40-66.
30. Stewart AL, Hays RD, Ware JE, Jr. The MOS short-form general health survey. Reliability and validity in a patient population. Med Care. 1988;26:724-735.
31. Stewart AL, Greenfield S, Hays RD, et al. Functional status and well-being of patients with chronic conditions. Results from the Medical Outcomes Study [published erratum appears in JAMA 1989;262:2542]. JAMA. 1989;262:907-913.
32. Aaronson NK, Acquadro C, Aloson J, et al. International Quality of Life Assessment (IQOLA) Project. Qual Life Res. 1992;1:349-351.
33. Fantl JA, Bump RC, Robinson D, McClish DK, Wyman JF. Efficacy of estrogen supplementation in the treatment of urinary incontinence. Obstet Gynecol. 1996;88:745-749.
34. Kelleher CJ. Quality of life. In: Cardozo L, editor. Urogynecology: The King's Approach. Edinburgh: Churchill Livingstone; 1997:673-688.
35. Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey: Manual and Interpretation Guide. Boston, Mass: Health Assessment Lab, New England Medical Center Health Institute; 1993.
36. Siddiqui O, Ali MW. A comparison of the random-effects pattern mixture model with last-observation-carried-forward (LOCF) analysis in longitudinal clinical trials with dropouts. J Biopharm Stat. 1998;8:545-563.
37. Sankoh AJ, Huque MF, Dubey SD. Some comments on frequently used multiple endpoint adjustment methods in clinical trials. Stat Med. 1997;16:2529-2542.
38. Pleil AM, Reese PR, Okano GJ, Kelleher CJ. Validation of King's Health Questionnaire in patients with symptoms of overactive bladder. Qual Life Res. 2000;9:347.
39. Reese PR, Pleil AM, Okano GJ, Kelleher CJ. Psychometric evaluation of the King's Health Questionnaire and the Short Form 36 in patients with overactive bladder receiving tolterodine. Qual Life Res. In press.
40. Wein AJ, Rovner ES. The overactive bladder: An overview for primary care health providers. Int J Fertil Womens Med. 1999;44:56-66.
41. Abrams P, Kelleher CJ, Kerr LA, Rogers RG. Overactive bladder significantly affects quality of life. Am J Manag Care. 2000;6:S580-S590.
42. Coyne K, Revicki D, Hunt T, et al. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: The OAB-q. Qual Life Res. 2002;11:563-574.
43. Pleil AM, Reese PR, Okano GJ, Kelleher CJ. Validation of King's Health Questionnaire in patients with symptoms of overactive bladder [abstract]. Qual Life Res. 2000;9:347.
44. Kelleher CJ, Pleil AM, Reese PR. Health related QoL of patients with overactive bladder receiving tolterodine once daily. Neurourology Urodynamics. 2000;19:519-520.
45. Kelleher C, Cardozo L, Khullar V, Salvatore S. A medium-term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. Br J Obstet Gynaecol. 1997;104:988-993.
46. Yarker YE, Goa KL, Fitton A. Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging. 1995;6:243-262.
47. Meyhoff HH, Gerstenberg TC, Nordling J. Placebo - The drug of choice in female motor urge incontinence? Br J Urol. 1983;55:34-37.
48. Abrams P, Larsson G, Chapple C, Wein AJ. Factors involved in the success of antimuscarinic treatment. BJU Int. 1999;83(suppl 2):42-47.
49. Chancellor M, Freedman S, Mitcheson HD, et al. Tolterodine, an effective and well tolerated treatment for urge incontinence and other overactive bladder symptoms. Clin Drug Invest. 2000;19:83-91.
50. Roberts RG. Current management strategies of overactive bladder. Patient Care. 2000;(winter suppl):22-30.
51. Pleil AM, Reese PR, Slaton TL, Okano GJ, Kelleher CJ. Minimally perceived differences of the King's Health Questionnaire: A comparison of results from two studies. Abstract presented at: Drug Information Association Quality of Life Conference; March, 2001.
52. Reese PR, Okano GJ, Pleil AM, Kelleher CJ. Minimally perceived difference of the King's Health Questionnaire in patients with symptoms of overactive bladder: A comparison of results from two studies. Abstract presented at: International Society for Quality of Life Research Annual Conference; October 29-31, 2000.